End of the beginning
CureFFI.org,
It’s now been 3 months since the first site began recruiting for Ionis’s ION717 ASO trial in prion disease (NCT06153966). A…
Results in from PRN100 antibody first-in-human dosing
CureFFI.org,
Figure 2 from [Mead 2022], showing the survival of patients treated with a PrP monoclonal antibody (red) versus historical…
PrP antibodies in humans: the experiments of nature
CureFFI.org,
introduction A powerful thing about human genetics is that it allows us to read out the experiments of nature that have…
Developments and challenges in degradation-targeting chimeras
CureFFI.org,
Back in 2015, I blogged about the buzz in the chemical biology world over targeted protein degradation: the use of chimeric…